1. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis. 2004;27(5):305-18.
2. Razavi MR, Shirzadi MR, Mohebali M, et al. Human cutaneous leishmaniosis in Iran, up to date-2019. J Arthropod Borne Dis. 2021;15(2):143-51.
3. Sharifi I, Khosravi A, Aflatoonian MR et al. Cutaneous leishmaniasis situation analysis in the Islamic Republic of Iran in preparation for an elimination plan. Front. Public Health. 2023; 11: 1091709. doi: 10.3389/fpubh.2023.1091709.
4. Tabasi M, Alesheikh AA, Sofizadeh A, et al. A spatio-temporal agent-based approach for modeling the spread of zoonotic cutaneous leishmaniasis in northeast Iran. Parasit Vectors. 2020;13(1):572.
5. Nieva CB, Cid AG, Romero AI, et al. An appraisal of the scientific current situation and new perspectives in the treatment of cutaneous leishmaniasis. Acta Trop. 2021;221:105988.
6. Asilian A, Sadeghinia A, Faghihi G, Momeni A. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime®) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime®) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol Venereol. 2004;43(4):281-3.
7. Mayrink W, Botelho ACdC, Magalhães PA, et al. Immunotherapy, immunochemoth-erapy and chemotherapy for American cutaneous leishmaniasis treatment. Rev Soc Bras Med Trop. 2006;39(1):14-21.
8. Currie MA. Treatment of cutaneous leishmaniasis by curettage. British Med J (Clinical research ed). 1983; 287(6399): 1105–1106.
9. Thornton SJ, Wasan KM. The reformulation of Amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis. Expert Opin Drug Deliv. 2009;6(3):271-84.
10. Wortmann G, Zapor M, Ressner R, et al. Lipsosomal Amphotericin B for treatment of cutaneous leishmaniasis. Am J Trop Med Hyg. 2010;83(5):1028-33.
11. Solomon M, Pavlotsky F, Leshem E, et al. Liposomal Amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica. J Eur Acad Dermatol Venereol. 2011;25(8):973-7.
12. Shirzadi MR. Lipsosomal Amphotericin B: a review of its properties, function, and use for treatment of cutaneous leishmaniasis. Res Rep Trop Med. 2019;10:11-18.
13. Reithinger R, Dujardin JC, Louzir H, et al. Cutaneous leishmaniasis. Lancet Infect Dis. 2007;7(9):581-96.
14. Sabzevari S, Teshnizi SH, Shokri A, et al. Cutaneous leishmaniasis in Iran: A systematic review and meta-analysis. Microb Pathog. 2021;152:104721.
15. Azim M, Khan SA, Ullah S, et al. Therapeutic advances in the topical treatment of cutaneous leishmaniasis: A review. PLoS Negl Trop Dis. 2021;15(3):e0009099.
16. Postigo JAR. Leishmaniasis in the world health organization eastern mediterranean region. Int J Antimicrob Agents. 2010;36:S62-S5.
17. Eiras DP, Kirkman LA, Murray HW. Cutaneous leishmaniasis: current treatment practices in the USA for returning travelers. Curr Treat Options Infect Dis. 2015;7(1):52-62.
18. Brito NC, Rabello A, Cota GF. Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review. PLoS One. 2017;12(9):e0184777.
19. . Blum J, Lockwood DN, Visser L, et al. Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis. Int Health. 2012;4(3):153-63.
20. Koff AB, Rosen T. Treatment of cutaneous leishmaniasis. J Am Acad Dermatol. 1994;31(5):693-708.
21. Palumbo E. Current treatment for cutaneous leishmaniasis: a review. Am J Ther. 2009;16(2):178-82.
22. Ramos H, Valdivieso E, Gamargo M, et al. Amphotericin B kills unicellular leishmanias by forming aqueous pores permeable to small cations and anions. J Membr Biol. 1996;152(1):65-75.
23. Laniado-Laborín R, Cabrales-Vargas MN. Amphotericin B: side effects and toxicity. Rev Iberoam Micol. 2009;26(4):223-7.
24. Rocio C, Amato VS, Camargo RA, et al. Liposomal formulation of Amphotericin B for the treatment of mucosal leishmaniasis in HIV-negative patients. Trans R Soc Trop Med Hyg. 2014;108(3):176-8.
25. Solomon M, Pavlotzky F, Barzilai A, Schwartz E. Liposomal Amphotericin B in comparison to sodium stibogluconate for Leishmania braziliensis cutaneous leishmaniasis in travelers. J Am Acad Dermatol. 2013;68(2):284-9.
26. Goyonlo VM, Vosoughi E, Kiafar B, et al. Efficacy of intralesional Amphotericin B for the treatment of cutaneous leishmaniasis. Indian J Dermatol. 2014;59(6):631.
27. Eskandari SE, Firooz A, Nassiri-Kashani M, et al. Safety evaluation of nano-liposomal formulation of Amphotericin B (sina ampholeish) in animal model as a candidate for treatment of cutaneous leishmaniasis. J Arthropod Borne Dis. 2018;12(3):269-75.
28. Eskandari SE, Firooz A, Nassiri-Kashani M, et al. Safety evaluation of topical application of nano-liposomal form of Amphotericin B (SinaAmpholeish) on healthy volunteers: phase I clinical trial. Iran J Parasitol. 2019;14(2):197-203.
29. Jaafari MR, Hatamipour M, Alavizadeh SH, et al. Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis. Int J Parasitol Drugs Drug Resist. 2019;11:156-65.
30. Eskandari SE, Khamesipour A, Jaafari MR, et al. Combination of topical liposomal Amphotericin B and Glucantime in comparison with glucantime alone for the treatment of anthroponotic cutaneous leishmaniasis (ACL) caused by Leishmania tropica: study protocol for a randomized, controlled trial. Iran J Microbiol. 2021;13(5):718-23.
31. Khamesipour A, Mohammadi A, Jaafari M, et al. Pilot study of safety and efficacy of topical liposomal Amphotericin B for cutaneous leishmaniasis caused by Leishmania major in Islamic Republic of Iran. East Mediterr Health J. 2022;28(9):658-63.
32. Guery R, Henry B, Martin-Blondel G, et al. Liposomal Amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea. PLoS Negl Trop Dis. 2017;11(11):e0006094.
33. Yardley V, Croft SL. Activity of liposomal Amphotericin B against experimental cutaneous leishmaniasis. Antimicrob Agents Chemother. 1997;41(4):752-6.
34. Hohl CM, Small SS, Peddie D, et al. Why clinicians don’t report adverse drug events: qualitative study. JMIR Public Health And Surveillance. 2018;4(1):e9282.
35. Santos CR, Tuon FF, Cieslinski J, et al. Comparative study on liposomal Amphotericin B and other therapies in the treatment of mucosal leishmaniasis: A 15-year retrospective cohort study. Plos One. 2019;14(6):e0218786.